Jones Trading upgrades Capricor stock rating ahead of FDA decision

AI Summary

Jones Trading upgraded its rating on Capricor Therapeutics stock ahead of an upcoming FDA decision. The headline gives no details on the rating change, the FDA decision, or its expected timing.